Erişkin çağı pnömokok aşılamalarının COVID-19 klinik seyri ile ilişkisi

Year 2024, Volume: 16 Issue: 3, 92 - 93, 31.12.2024

Ülkü Sur Ünal

https://doi.org/10.35514/mtd.2024.119

Abstract

Karaçepiş ve arkadaşlarının COVID-19 pandemisinin erişkin aşılamalar üzerindeki etkilerini ele alan makalesini ilgiyle okudum. Makalede COVID-19 pandemisi dönemindeki erişkin çağı pnömokok aşılamasındaki artışın halka yayılan bilgilere dayandığı belirtilmiştir. Bunun yanında pnömokok aşılamalarının COVID-19 klinik seyri üzerine etkilerini araştıran birçok çalışma bulunmaktadır. Bazı çalışmalar pnömokok aşısının SARS-CoV-2 enfeksiyonuna karşı orta düzeyde koruma sağladığını belirtirken, özellikle erken dönemde yapılan çalışmalar herhangi bir etkisinin olmadığını ifade etmişlerdir. Daha güncel ve kapsamlı araştırmaların bu konuda net bir anlayış sunacağına inanıyorum.

Keywords

Pnömokok aşıları , COVID-19 , İletişim

The relationship between adult pneumococcal vaccination and the clinical course of COVID-19

Abstract

I read with great interest the article by Karacepis and colleagues discussing the effects of the COVID-19 pandemic on adult vaccinations. The article states that the increase in adult pneumococcal vaccinations during the COVID-19 pandemic is based on information spread among the public. Additionally, there are many studies investigating the effects of pneumococcal vaccinations on the clinical course of COVID-19. While some studies indicate that the pneumococcal vaccine provides moderate protection against SARS-CoV-2 infection, particularly those conducted in the early stages have stated that there was no effect. I believe that more recent and comprehensive research will provide a clearer understanding of this issue.

Keywords

Pneumococcal Vaccines , COVID-19 , Communication

References

• 1.Karaçepiş C, Mutlu HH, Gülek A, Mutlu HH. The impact of covid-19 pandemic on recommended adult vaccination in elderly: A hospital-based study. Maltepe tıp derg. 2024;16(2):28-34. doi: 10.35514/mtd.2024.108.
• 2.Centers for Disease Control and Prevention. Vaccine Information Statement: Pneumococcal Conjugate Vaccine - What you need to know [Internet]. 2023 Dec. Available from: www.hrsa.gov/vaccinecompensation
• 3.Lewnard JA, Hong V, Grant LR, Ackerson BK, Bruxvoort KJ, Pomichowski M, Arguedas A, Cané A, Jodar L, Gessner BD, Tartof SY. Association of Pneumococcal Conjugate Vaccination With Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Older Adult Recipients of Coronavirus Disease 2019 Vaccines: A Longitudinal Cohort Study. J Infect Dis. 2024 Nov 15;230(5):e1082-e1091. doi: 10.1093/infdis/jiae387.
• 4.Kapoula GV, Vennou KE, Bagos PG. Influenza and Pneumococcal Vaccination and the Risk of COVID-19: A Systematic Review and Meta-Analysis. Diagnostics (Basel). 2022 Dec 7;12(12):3086. doi: 10.3390/diagnostics12123086.
• 5.Pastorino R, Villani L, La Milia DI, Ieraci R, Chini F, Volpe E, et al. Influenza and pneumococcal vaccinations are not associated to COVID-19 outcomes among patients admitted to a university hospital. Vaccine. 2021 Jun 11;39(26):3493–7. doi: 10.1016/j.vaccine.2021.05.015.
• 6.Taks EJM, Föhse K, J C F M Moorlag S, Hoogerwerf J, van Crevel R, van Werkhoven CH, Netea MG, Ten Oever J. Routine vaccination for influenza and pneumococcal disease and its effect on COVID-19 in a population of Dutch older adults. Vaccine X. 2023 Jul 6;14:100344. doi: 10.1016/j.jvacx.2023.100344.